HPLC methods for Radiopharmaceuticals

Radiopharma-ceutical	Column	Isocratic or gradient	Solvent(s)	Reference
^99mTc-sestamibi	C-8	gradient	A: 50 mM ammonium sulphate B: methanol 0%B to 95%B over 5 minutes	Carvalho 1992 [1]
^99mTc-sestamibi	C-18	isocratic	A: methanol B: 50 mM ammonium sulphate C: acetonitrile A:B:C 45:35:20	Hung 1991 [2]
^99mTc-tetrofosmin	PRP-1	gradient	A: 10 mM phosphate buffer pH 7.5 B: tetrahydrofuran 0%B to 100%B over 17 minutes	Kelly 1993 [3]
^99mTc-tetrofosmin	PRP-1	isocratic	A: acetonitrile B: 10 mM ammonium carbonate A:B 70:30	Millar 1999 [15]
^99mTc-tetrofosmin	PRP-1	isocratic	A: 5 mM monopotassium phosphate B: acetonitrile A:B 50:50	Cagnolini 1998 [16]
^99mTc-MAG3	C-18	isocratic with wash	A: ethanol B: 10 mM phosphate buffer pH 6 A:B 5:95 after peak, wash with methanol-water 90:10	Millar 1990 [4]
^99mTc-MAG3	C-18	gradient	A: 10 mM potassium phosphate with 1% triethylamine pH 5 B: tetrahydrofuran 0%B to 8%B over 30 minutes	Shattuck 1994 [5]
^99mTc-exametazime	PRP-1	gradient	A: 20 mM phosphate buffer pH 7.4 B: tetrahydrofuran 0%B to 25%B over 6 minutes	Neirinckx 1987 [6]
^99mTc-exametazime	PRP-1	gradient	A: 10 mM potassium phosphate pH 7 or water containing 1% methanol B: acetonitrile 0%B to 50%B over 5 minutes	Hung 1988 [7]
^99mTc-exametazime	PRP-1	gradient	A: 50 mM sodium acetate pH 5.6 B: tetrahydrofuran 0%B to 100%B over 17 minutes	Weisner 1993 [8]
^99mTc-depreotide	C-18	gradient	A: 0.1% TFA in water B: 0.1% TFA in acetonitrile 20%B to 27%B over 30 minutes	Zinn 2000 [9]
^123/131I-MIBG	C-18	isocratic	A: 100 mM sodium phosphate B: tetrahydrofuran A:B 88:12	Wieland 1980 [10]
¹²³I-ioflupane	C-18	isocratic	A: methanol B water C: triethylamine A:B:C 85:15:0.2	Baldwin 1995 [11]
¹²³I-iomazenil	C-18	isocratic	A: methanol B: water A:B 55:45	Zoghbi 1992 [12]
¹²⁵I-albumin	C-4	gradient	A: 0.1% TFA in water B: 0.1% TFA in acetonitrile 35%B to 90%B in 10 minutes	Liverpool
¹¹¹In-octreotide	C-18	gradient	A: saline B: methanol 40%B to 80%B in 20 minutes	Krenning 1992 [13]
¹⁸F-FDG	amino	isocratic	A: acetonitrile B: water A:B 95:5	Hamacher 1986 [14]

Back to Radiopharmacy Handbook Index

References

1. Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, Piwnica-Worms D. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1522.

2. Hung JC, Wilson ME, Brown ML, Gibbons RJ. Rapid preparation and quality control method for technetium-99m-2-methoxy isobutyl isonitrile (technetium-99m-sestamibi). J Nucl Med 1991; 32: 2162-2168.

3. Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, Chiu KW, Edwards B, Gill HK, McPartlin M. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993; 34: 222-227.

4. Millar AM, Wilkinson AG, McAteer E, Best JJK. ⁹⁹Tc^m-MAG3: in vitro stability and in vivo behaviour at different times after preparation. Nucl Med Commun 1990; 11: 405-412.

5. Shattuck LA, Eshima D, Taylor AT, Anderson TL, Graham DL, Latino FA, Payne SE. Evaluation of the hepatobiliary excretion of technetium-99m-MAG3 and reconstitution factors affecting radiochemical purity. J Nucl Med 1994; 35: 349-355.

6. Neirinckx RD, Canning LR, Piper IM, Nowotnik DP, Pickett RD, Holmes RA, Volkert WA, Forster AM, Weisner PS, Marriott JA, Chaplin SB. Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 1987; 28: 191-202.

7. Hung JC, Corlija M, Volkert WA, Holmes RA. Kinetic analysis of technetium-99m d,l-HMPAO decomposition in aqueous media. J Nucl Med 1988; 29: 1568-1576.

8. Weisner PS, Bower GR, Dollimore LA, Forster AM, Higley B, Storey AE. A method for stabilising technetium-99m exametazime prepared from a commercial kit. Eur J Nucl Med 1993; 20: 661-666.

9. Zinn KR, Buchsbaum DJ, Chaudhuri TR, Mountz JM, Grizzle WE, Rogers BE. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with ^99mTc or ¹⁸⁸Re. J Nucl Med 2000; 41: 887-895.

10. Wieland DM, Wu JI, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [¹³¹I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.

11. Baldwin RM, Zea-Ponce Y, al-Tikriti MS, Zoghbi SS, Seibyl JP, Charney DS, Hoffer PB, Wang S, Milius RA, Neumeyer JL, Innis RB. Regional brain uptake and pharmacokinetics of [¹²³I]N-w-fluoroalkyl-2b-carboxy-3b-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol 1995; 22: 211-219.

12. Zoghbi SS, Baldwin RM, Seibyl JP, al-Tikriti MS, Zea-Ponce Y, Laruelle M, Sybirska EH, Woods SW, Goddard AW, Malison RT, Zimmerman R, Charney DS, Smith EO, Hoffer PB, Innis RB. Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [¹²³I]iomazenil in human and non-human primates. Nucl Med Biol 1992; 19: 881-888.

13. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.

14. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecitic synthesis of no-carrier-added 2-[¹⁸F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-238.

15. Graham D, Millar AM. Artefacts in the thin-layer chromatographic analysis of 99Tcm-tetrofosmin injections. Nucl Med Commun 1999; 20: 439-444.

16. Cagnolini A, Whitener D, Jurisson S. Comparison of the kit performance of three 99mTc myocardial perfusion agents. Nucl Med Biol 1998; 25: 435-439 (also used same system for sestamibi)